4784 T3D4729 Diclofenac A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt. 15307-86-5 3033 C14H11Cl2NO2 White powder. 283-285°C 2.37 mg/L (at 25°C) Completely absorbed from the gastrointestinal tract. The antiinflammatory effects of diclofenac are believed to be due to inhibition of both leukocyte migration and the enzyme cylooxygenase (COX-1 and COX-2), leading to the peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis is responsible for the analgesic effects of diclofenac. Antipyretic effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat dissipation. Hepatic. Route of Elimination: Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites. Little or no free unchanged diclofenac is excreted in the urine. Approximately 65% of the dose is excreted in the urine and approximately 35% in the bile as conjugates of unchanged diclofenac plus metabolites. Half Life: 2 hours LD<sub>50</sub>=390mg/kg (orally in mice) No indication of carcinogenicity to humans (not listed by IARC). For the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis. Symptoms of overdose include loss of consciousness, increased intracranial pressure, and aspiration pneumonitis. 2014-09-11T05:13:44Z 2014-12-24T20:26:56Z Diclofenac C01690 4507 DB00586 true OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl C14H11Cl2NO2 InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19) InChIKey=DCOPUUMXTXDBNB-UHFFFAOYSA-N 296.149 295.016684015 Exogenous Solid 4.51 CHEMBL139 2925 <p>Takuzo Kamishita, &#8220;Gel preparations for topical application of diclofenac sodium.&#8221; U.S. Patent US4670254, issued October, 1983.</p>